These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34518444)

  • 1. Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
    Ryan DH
    J Obes Metab Syndr; 2021 Sep; 30(3):196-208. PubMed ID: 34518444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs for Treating Obesity.
    Ryan DH
    Handb Exp Pharmacol; 2022; 274():387-414. PubMed ID: 34783910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semaglutide as a promising antiobesity drug.
    Christou GA; Katsiki N; Blundell J; Fruhbeck G; Kiortsis DN
    Obes Rev; 2019 Jun; 20(6):805-815. PubMed ID: 30768766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the pipeline for future medications for obesity?
    Melson E; Ashraf U; Papamargaritis D; Davies MJ
    Int J Obes (Lond); 2024 Feb; ():. PubMed ID: 38302593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity.
    Trapp CM; Censani M
    Curr Opin Endocrinol Diabetes Obes; 2023 Apr; 30(2):136-140. PubMed ID: 36722447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-Weekly Semaglutide for Weight Management: A Clinical Review.
    Fornes A; Huff J; Pritchard RI; Godfrey M
    J Pharm Technol; 2022 Aug; 38(4):239-246. PubMed ID: 35832567
    [No Abstract]   [Full Text] [Related]  

  • 7. Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
    Colin IM; Gérard KM
    touchREV Endocrinol; 2022 Jun; 18(1):35-42. PubMed ID: 35949360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity.
    Pressley H; Cornelio CK; Adams EN
    J Pharm Technol; 2022 Dec; 38(6):368-373. PubMed ID: 36311304
    [No Abstract]   [Full Text] [Related]  

  • 9. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
    Rodriguez PJ; Goodwin Cartwright BM; Gratzl S; Brar R; Baker C; Gluckman TJ; Stucky NL
    JAMA Intern Med; 2024 Sep; 184(9):1056-1064. PubMed ID: 38976257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Setmelanotide: First Approval.
    Markham A
    Drugs; 2021 Feb; 81(3):397-403. PubMed ID: 33638809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide.
    Wabitsch M; Farooqi S; Flück CE; Bratina N; Mallya UG; Stewart M; Garrison J; van den Akker E; Kühnen P
    J Endocr Soc; 2022 Jun; 6(6):bvac057. PubMed ID: 35528826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
    Jung HN; Jung CH
    J Obes Metab Syndr; 2022 Mar; 31(1):28-36. PubMed ID: 35314521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
    Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A
    Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.
    Srivastava G; Apovian C
    Curr Obes Rep; 2018 Jun; 7(2):147-161. PubMed ID: 29504049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity.
    Nguyen T; Wong E; Cope R
    Am J Ther; 2023 Jul-Aug 01; 30(4):e347-e352. PubMed ID: 37449929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
    Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
    Scheen AJ
    Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.
    Bays HE; Fitch A; Christensen S; Burridge K; Tondt J
    Obes Pillars; 2022 Jun; 2():100018. PubMed ID: 37990711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
    Ryan DH; Lingvay I; Colhoun HM; Deanfield J; Emerson SS; Kahn SE; Kushner RF; Marso S; Plutzky J; Brown-Frandsen K; Gronning MOL; Hovingh GK; Holst AG; Ravn H; Lincoff AM
    Am Heart J; 2020 Nov; 229():61-69. PubMed ID: 32916609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.